1588
The development of systemic lupus erythematosus (SLE) after 38 months of therapy with recombinant human interferon gamma (rIFN-gamma) was observed in a patient with rheumatoid arthritis.
 a patient with rheumatoid arthritis.: Subject; systemic lupus erythematosus: Effect; after 38 months: Treatment; recombinant human interferon gamma: Treatment; after 38 months: Treatment.Time_elapsed; recombinant human interferon gamma: Treatment.Drug; rheumatoid arthritis.: Treatment.Disorder
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 a patient with rheumatoid arthritis.: Subject; systemic lupus erythematosus: Effect; after 38 months: Treatment; recombinant human interferon gamma: Treatment; after 38 months: Treatment.Time_elapsed; recombinant human interferon gamma: Treatment.Drug; rheumatoid arthritis.: Treatment.Disorder